Clinical effects of Emblica officinalis fruit consumption on cardiovascular disease risk factors: a systematic review and meta-analysis.
Amla
Atherosclerosis
Cardiovascular disease
Cholesterol
Chronic disease
Emblica officinalis
Inflammation
Lipids
Meta-analysis
Phyllanthus emblica
Journal
BMC complementary medicine and therapies
ISSN: 2662-7671
Titre abrégé: BMC Complement Med Ther
Pays: England
ID NLM: 101761232
Informations de publication
Date de publication:
09 Jun 2023
09 Jun 2023
Historique:
received:
09
09
2021
accepted:
13
05
2023
medline:
12
6
2023
pubmed:
10
6
2023
entrez:
9
6
2023
Statut:
epublish
Résumé
Emblica officinalis (EO) fruit consumption has been found to have a beneficial effect on cardiovascular disease (CVD) physiological risk factors in preliminary clinical intervention trials; however, questions remain regarding the overall effectiveness of EO on CVD risk. The purpose of this systematic review and meta-analysis is to: 1) systematically describe the clinical research examining EO; and 2) quantitatively assess the effects of EO on CVD physiological risk factors. The Pubmed, Embase, Web of Science, and Google Scholar electronic platforms were searched for relevant randomized controlled trials (RCTs) published until April 7, 2021. Studies were included if they involved adults (age ≥ 18 years) ingesting a form of EO fruit; included blood lipids, blood pressure, and/or inflammatory biomarkers as outcomes; had clearly defined intervention and control treatments with pre- and post-intervention data; were peer-reviewed; and were written in English. Studies were excluded if they compared EO with another risk reduction intervention without a usual care control group. RCTs were assessed for methodological quality using the Cochrane risk-of-bias version 2 (ROB2) tool, qualitatively described, and quantitatively evaluated using random and fixed effect meta-analysis models. A total of nine RCTs (n = 535 participants) were included for review. Included studies followed parallel-group (n = 6) and crossover (n = 3) designs, with EO dosage ranging from 500 mg/day to 1500 mg/day, and treatment duration ranging from 14 to 84 days. Meta-analyses revealed EO to have a significant composite effect at lowering low-density lipoprotein cholesterol (LDL-C; Mean difference (MD) = -15.08 mg/dL [95% Confidence interval (CI) = -25.43 to -4.73], I Due to statistical and clinical heterogeneity in the limited number of clinical trials to date, the promising effects of EO on physiologic CVD risk factors in this review should be interpreted with caution. Further research is needed to determine if EO offers an efficacious option for primary or secondary prevention of CVD as either monotherapy or adjunct to evidence-based dietary patterns and/or standard pharmacotherapy.
Sections du résumé
BACKGROUND
BACKGROUND
Emblica officinalis (EO) fruit consumption has been found to have a beneficial effect on cardiovascular disease (CVD) physiological risk factors in preliminary clinical intervention trials; however, questions remain regarding the overall effectiveness of EO on CVD risk. The purpose of this systematic review and meta-analysis is to: 1) systematically describe the clinical research examining EO; and 2) quantitatively assess the effects of EO on CVD physiological risk factors.
METHODS
METHODS
The Pubmed, Embase, Web of Science, and Google Scholar electronic platforms were searched for relevant randomized controlled trials (RCTs) published until April 7, 2021. Studies were included if they involved adults (age ≥ 18 years) ingesting a form of EO fruit; included blood lipids, blood pressure, and/or inflammatory biomarkers as outcomes; had clearly defined intervention and control treatments with pre- and post-intervention data; were peer-reviewed; and were written in English. Studies were excluded if they compared EO with another risk reduction intervention without a usual care control group. RCTs were assessed for methodological quality using the Cochrane risk-of-bias version 2 (ROB2) tool, qualitatively described, and quantitatively evaluated using random and fixed effect meta-analysis models.
RESULTS
RESULTS
A total of nine RCTs (n = 535 participants) were included for review. Included studies followed parallel-group (n = 6) and crossover (n = 3) designs, with EO dosage ranging from 500 mg/day to 1500 mg/day, and treatment duration ranging from 14 to 84 days. Meta-analyses revealed EO to have a significant composite effect at lowering low-density lipoprotein cholesterol (LDL-C; Mean difference (MD) = -15.08 mg/dL [95% Confidence interval (CI) = -25.43 to -4.73], I
CONCLUSIONS
CONCLUSIONS
Due to statistical and clinical heterogeneity in the limited number of clinical trials to date, the promising effects of EO on physiologic CVD risk factors in this review should be interpreted with caution. Further research is needed to determine if EO offers an efficacious option for primary or secondary prevention of CVD as either monotherapy or adjunct to evidence-based dietary patterns and/or standard pharmacotherapy.
Identifiants
pubmed: 37296402
doi: 10.1186/s12906-023-03997-8
pii: 10.1186/s12906-023-03997-8
pmc: PMC10251691
doi:
Substances chimiques
Cholesterol
97C5T2UQ7J
Cholesterol, LDL
0
Types de publication
Meta-Analysis
Systematic Review
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
190Informations de copyright
© 2023. The Author(s).
Références
Stat Med. 2002 Jun 15;21(11):1539-58
pubmed: 12111919
Indian J Clin Biochem. 2008 Oct;23(4):378-81
pubmed: 23105791
J Agric Food Chem. 2007 Sep 19;55(19):7744-52
pubmed: 17715896
Indian J Pharmacol. 2012 Mar;44(2):238-42
pubmed: 22529483
Can J Cardiol. 2016 Nov;32(11):1263-1282
pubmed: 27712954
J Ethnopharmacol. 2011 Jan 27;133(2):856-65
pubmed: 21093572
BMC Complement Altern Med. 2019 May 6;19(1):97
pubmed: 31060549
Am J Chin Med. 2009;37(1):19-25
pubmed: 19222108
Pharmazie. 2003 Oct;58(10):753-5
pubmed: 14609291
Ann Neurosci. 2016 Oct;23(4):218-229
pubmed: 27780989
Evid Based Complement Alternat Med. 2020 Oct 7;2020:8592869
pubmed: 33082832
J Am Coll Cardiol. 2010 Sep 28;56(14):1113-32
pubmed: 20863953
Biomed Pharmacother. 2017 Sep;93:1292-1302
pubmed: 28747010
Indian J Med Res. 2008 Aug;128(2):188-93
pubmed: 19001683
BMJ. 2021 Mar 29;372:n71
pubmed: 33782057
Syst Rev. 2017 Dec 06;6(1):245
pubmed: 29208034
Phytother Res. 2021 Jun;35(6):3275-3285
pubmed: 33570228
J Nutr Sci Vitaminol (Tokyo). 2005 Dec;51(6):413-8
pubmed: 16521700
Environ Toxicol Pharmacol. 2012 Nov;34(3):801-10
pubmed: 23058484
J Ethnopharmacol. 2008 Sep 2;119(1):53-7
pubmed: 18588964
Phytomedicine. 2003;10(6-7):583-9
pubmed: 13678247
Phytomedicine. 2002 Sep;9(6):515-22
pubmed: 12403160
Prog Cardiovasc Dis. 2018 May - Jun;61(1):43-53
pubmed: 29807048
Adv Nutr. 2020 Sep 1;11(5):1150-1160
pubmed: 32330233
J Alzheimers Dis. 2020;74(3):713-733
pubmed: 32083581
Clin Chem. 1972 Jun;18(6):499-502
pubmed: 4337382
J Ethnopharmacol. 2004 Nov;95(1):83-5
pubmed: 15374611
Int J Cardiol. 2015 Dec;201 Suppl 1:S1-7
pubmed: 26747389
Res Synth Methods. 2021 Jan;12(1):55-61
pubmed: 32336025
Int J Food Sci Nutr. 2011 Sep;62(6):609-16
pubmed: 21495900
Wound Repair Regen. 2009 Jan-Feb;17(1):99-107
pubmed: 19152656
Eur J Clin Nutr. 1988 Nov;42(11):939-44
pubmed: 3250870
Int J Epidemiol. 2002 Feb;31(1):140-9
pubmed: 11914310
Diabetes Metab Syndr Obes. 2013 Jul 26;6:275-84
pubmed: 23935377
Circulation. 2020 Mar 3;141(9):e139-e596
pubmed: 31992061
Phytomedicine. 2014 Apr 15;21(5):579-85
pubmed: 24291054
J Ethnopharmacol. 1996 Feb;50(2):61-8
pubmed: 8866725
BMJ. 2019 Aug 28;366:l4898
pubmed: 31462531
Pharmacognosy Res. 2014 Jan;6(1):29-35
pubmed: 24497739
JAMA. 2011 Aug 24;306(8):831-9
pubmed: 21862744
Contemp Clin Trials Commun. 2019 Nov 27;17:100499
pubmed: 31890983
J Cardiovasc Thorac Res. 2018;10(3):118-128
pubmed: 30386531
J Ethnopharmacol. 2002 Jan;79(1):81-7
pubmed: 11744299
J Med Food. 2015 Apr;18(4):415-20
pubmed: 25756303
Evid Based Complement Alternat Med. 2011;2011:146808
pubmed: 21076542
Pharmacol Res. 2016 Sep;111:180-200
pubmed: 27320046
Res Synth Methods. 2017 Mar;8(1):5-18
pubmed: 28058794
BMC Complement Altern Med. 2019 Jan 22;19(1):27
pubmed: 30670010
Food Funct. 2017 Feb 22;8(2):842-850
pubmed: 28128372
Indian J Pharm Sci. 2008 Jul-Aug;70(4):504-7
pubmed: 20046781